Audited Financial Results for the quarter and year ended March 31, 2026.
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.3 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
HCG reported standalone revenue from operations of Rs 135,937 lakhs for FY26, up 6.5% from Rs 127,652 lakhs in FY25. However, profit after tax declined 9% to Rs 1,458 lakhs from Rs 1,605 lakhs, primarily due to significant exceptional items totaling Rs 5,538 lakhs. Key exceptional items include Rs 3,752 lakhs impairment on BACC divestment, Rs 3,000 lakhs impairment on HCG Kolkata Cancer Care LLP, partially offset by Rs 2,000 lakhs reversal for HCG Manavata Oncology LLP. The company completed a Rs 424.69 crore rights issue in March 2026, with proceeds still unutilized. Q4 standalone result shows a loss of Rs 895 lakhs due to exceptional items. BACC, engaged in fertility services, is being divested to Inviga Healthcare Fund I for Rs 3,764 lakhs as a related party transaction. Auditors BSR & Co. LLP issued an unmodified (clean) opinion.
The stock may face pressure from PAT decline and Q4 losses despite revenue growth. The BACC divestment signals strategic focus on core oncology business. Strong cash position from rights issue provides flexibility for debt reduction or growth, though revenue growth remains modest at 6.5%.